AstraZeneca acquires Amylin Pharmaceuticals from Bristol-Meyers Squibb
In February 2014, Amylin Pharmaceuticals was acquired by AstraZeneca.
Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.
August 9th, 2012
Bristol-Myers Squibb Company announced today that it has completed its previously announced acquisition of Amylin Pharmaceuticals.
Challenging Science. Changing Lives.
Amylin Pharmaceuticals is an exceptional company of extraordinary people. Their willingness to challenge conventional thinking as much as they challenge themselves, their resolve, resiliency and passion for the patient are improving the lives of millions.
- February 2014
AstraZeneca completes aquisition of Amylin Pharmaceuticals from Bristol-Meyers Squibb
- August 9th, 2012
Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through
Bristol-Myers Squibb’s Acquisition of Amylin.